First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): Response and survival results up to five years from the KEYNOTE-052 phase 2 study.

被引：22

作者：

O'Donnell, Peter H.

Balar, Arjun Vasant

Vuky, Jacqueline

Castellano, Daniel

Bellmunt, Joaquim

Powles, Thomas

Bajorin, Dean F.

Grivas, Petros

Hahn, Noah M.

Plimack, Elizabeth R.

Xu, Jin Zhi

Godwin, James Luke

Moreno, Blanca Homet

De Wit, Ronald

机构：

[1] Univ Chicago, Chicago, IL 60637 USA

[2] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA

[3] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[4] Hosp Univ 12 Octubre, Madrid, Spain

[5] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA

[6] Queen Mary Univ London, Barts Canc Inst, London, England

[7] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[8] Univ Washington, Seattle, WA 98195 USA

[9] Johns Hopkins Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[10] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[11] Merck & Co Inc, Kenilworth, NJ USA

[12] Erasmus MC Canc Inst, Rotterdam, Netherlands

来源：

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.4508

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4508

引用

页数：3